This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
CORE-001
CS-003
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Decipher Genomic Classifier
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
WCET 2024
BCAN TT 2024
SNMMI 2024
ASCO 2024
AUA 2024
All Conferences
View All
PCF
UroToday Home
Conference Highlights
ESMO 2022
ESMO 2022 Testicular and Penile Cancer
Conferences
ESMO 2022
Prostate Cancer
Bladder Cancer
Testicular and Penile Cancer
Press Releases
Kidney Cancer
ESMO 2022 Testicular and Penile Cancer
Viewing 1-20 of 82 articles
ESMO 2022: Invited Discussant: Results of COSMIC-313
ESMO 2022: Invited Discussant: Results of RADICALS-HD
ESMO 2022: Observations on the Biology of PSMA Implications for Targeting
ESMO 2022: Lu-PSMA for Prostate Cancer Treatment
ESMO 2022: Latest Imaging Advances in PET and Beyond Translated to Bladder and Kidney Cancers
ESMO 2022: PSMA Targeted T Cell Engagers
ESMO 2022: Multidisciplinary Updates in Biomarkers in Urinary Cancers: The Microbiome
ESMO 2022: Invited Discussant: The Phase III VESPER Trial & the Phase III CheckMate 274 Trial
ESMO 2022: Pure or Mixed Basal/squamous Tumours Present Decreased Outcomes After Neoadjuvant Chemotherapy in the GETUG-AFU V05 VESPER Trial
ESMO 2022: PSMA for Diagnosis and Staging
ESMO 2022: Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma of IMDC Intermediate or Poor Risk (COSMIC-313)
ESMO 2022: Duration of Androgen Deprivation Therapy with Post-Operative Radiotherapy for Prostate Cancer First Results of the RADICALS-HD Trial ISRCTN40814031
ESMO 2022: Invited Discussant: BIONIKK trial, Changes in Gut Microbiota, & LITESPARK-004 trial
ESMO 2022: Invited Discussant: Results of the Phase 2 LITESPARK-003 Trial
ESMO 2022: Longitudinal Analysis Reveals Gut Microbiota Shift During Standard Therapies in Metastatic Renal Cell Carcinoma (mRCC)
ESMO 2022: Invited Discussant: The Results of the PIVOT-09 Trial & the Role of Enfortumab Vedotin
ESMO 2022: Phase 2 Study of Belzutifan plus Cabozantinib as First-Line Treatment of Advanced Renal Cell Carcinoma Cohort 1 of LITESPARK-003
ESMO 2022: Bempegaldesleukin plus Nivolumab Compared to the Investigator’s Choice of Sunitinib or Cabozantinib in Previously Untreated Advanced Renal Cell Carcinoma Results from a Phase 3 Randomized Study
ESMO 2022: Study EV-103 Cohort K: Antitumor Activity of Enfortumab Vedotin Monotherapy or in Combination with Pembrolizumab in Previously Untreated Cisplatin-Ineligible Patients with Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
ESMO 2022: Tumor and Immune Features Associated with Disease-Free Survival with Adjuvant Nivolumab in the Phase 3 CheckMate 274 Trial
1
2
3
4
5
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free